title: Evolution of ciclosporin nephrotoxicity in patients treated for autoimmune uveitis.
abstract: Among 73 patients treated with ciclosporin (CS) for autoimmune uveitis, a 50% elevation of serum creatinine was observed in 37% within 3 months of starting CS and in 25% after more than 6 months of relatively uncomplicated therapy. Sequential renal function and histologic evaluations were performed in 17 patients to further characterize the nephrotoxic effects of long-term CS therapy. Inulin clearance remained essentially unchanged in 12 patients despite CS dosage reductions in the majority. In 2 such patients, repeat renal biopsy specimens revealed evidence of progressive irreversible kidney injury even though renal function was stable. Inulin clearance decreased substantially in 3 patients; in 1 case a follow-up renal biopsy showed increased severity of chronic histologic change. For 2 patients, the inulin clearance more than doubled after CS dosage reduction; and in 1 of those cases, repeat renal biopsy showed no evidence of progressive renal scarring. Overall, the morphologic attributes of irreversible kidney injury (designated by a chronicity index including glomerular sclerosis, tubular atrophy and interstitial fibrosis) were increased in 3 of 6 follow-up renal biopsy specimens. Histologic alterations of renal arterioles, including hyaline change, were observed in all CS-treated patients. The hyaline change of arterioles was either extensive in the first renal biopsy specimen or became extensive in the second biopsy in the 3 cases manifesting an increased chronicity index on the follow-up renal biopsy. Thus, parenchymal injury can progress in some cases despite CS dosage reduction and stable renal function; renal arteriolar histologic change is a prominent finding in these patients. Patients that exhibit a substantial improvement in renal function after dosage reduction may experience a more favorable course.
authors: Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.
authors: H A
authors: HA
authors: Austin
authors: A G
authors: AG
authors: Palestine
authors: S G
authors: SG
authors: Sabnis
authors: J E
authors: JE
authors: Balow
authors: H G
authors: HG
authors: Preuss
authors: R B
authors: RB
authors: Nussenblatt
authors: T T
authors: TT
authors: Antonovych
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy*; D003524:Cyclosporins / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000139:chemically induced*; D007676:Kidney Failure, Chronic / Q000139:chemically induced*; D007677:Kidney Function Tests; D013997:Time Factors; D014605:Uveitis / Q000188:drug therapy*
chemical_list: D003524:Cyclosporins